Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5549-5549
Author(s):  
David M. O'Malley ◽  
Lainie P. Martin ◽  
Lucy Gilbert ◽  
Ignace Vergote ◽  
Ursula A. Matulonis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Folate Receptor ◽  
Activity Profile ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Platinum Resistant ◽  
Phase 1B ◽  
Antibody Drug

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

2020 ◽  
Vol 156 (3) ◽  
pp. e15-e16
Author(s):  
Kathleen G. Essel ◽  
Lainie P. Martin ◽  
David M. O’Malley ◽  
Ursula Matulonis ◽  
Jason A. Konner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Safety Profile ◽  
Folate Receptor ◽  
Recurrent Ovarian Cancer ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document